Immunoregulation in pancreatic cancer patients.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Immunoregulation in pancreatic cancer patients.

Cancer Immunol Immunother. 1999 Aug;48(5):270-9. Unique Identifier : AIDSLINE MED/99405749
Plate JM; Shott S; Harris JE; Section of Medical Oncology, Department of Medicine,; Rush-Presbyterian St. Luke's Medical Center, Chicago, IL 60612,; USA. jplate@sispro.sis.rpslmc.edu

Abstract: Metastatic pancreatic cancer is one of the most aggressive cancer known in man yet specific antitumor immunity has been demonstrated in lymph nodes draining the sites of pancreatic tumors. Despite this immunity, pancreatic cancer patients suffer a quick demise. To further define tumor immunity in patients with metastatic pancreatic cancer, we sought to characterize helper T cell subsets, serum cytokines, cellular cytotoxicity that is both T-cell and non-T cell mediated, as well as known tumor-derived immunosuppressive products that may be present in their peripheral blood. Significantly heightened levels of interleukin 2 (IL-2), a Th1 cytokine, were found in patients before treatment with chemotherapy while serum IL-10, a Th2 cytokine, were at significantly lower levels than observed in normal donors tested between their fifth and seventh decades of life. IL-10 levels increased progressively with age as a serum-bound protein in normal, healthy donors tested between the ages of 24 through 61. An age associated progression of increased IL-10 levels was not observed in pancreatic cancer patients. Few patients had detectable serum levels of soluble fas ligand but approximately half had elevated levels of a tumor marker, detected with the CA-15.3 assay, known as soluble MUCIN 1 (MUC1). Cell mediated cytotoxicity including T-cell mediated killing of pancreatic tumor cell lines was detected in many patients. These data suggest that pancreatic cancer patients have activated type 1 helper T cells that can support development of cell-mediated immunity, and that their sera contain lowered levels of the "anti-inflammatory" type 2 cytokine, IL-10.

Keywords: JOURNAL ARTICLE Age Factors Aged Aged, 80 and over Antigens, CD3/IMMUNOLOGY Case-Control Studies Cytokines/*IMMUNOLOGY CA-15-3 Antigen/IMMUNOLOGY CA-19-9 Antigen/IMMUNOLOGY Dose-Response Relationship, Immunologic Female Human Interleukin-10/BLOOD/IMMUNOLOGY Interleukin-2/BLOOD/IMMUNOLOGY Male Membrane Glycoproteins/IMMUNOLOGY Middle Age Neoplasm Metastasis/IMMUNOLOGY Pancreatic Neoplasms/*IMMUNOLOGY Peptide Fragments/IMMUNOLOGY Radioimmunoassay Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger/ANALYSIS Support, Non-U.S. Gov't T-Lymphocytes, Cytotoxic/IMMUNOLOGY Th1 Cells/IMMUNOLOGY Th2 Cells/IMMUNOLOGY
991230
A99C1004

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .